According to drug producers, an Alzheimer’s treatment reduces the progression of cognitive impairment in clinical trials.
CNN —Lecanemab, a monoclonal antibody therapy for Alzheimer's disease, delays the progression of cognitive deterioration by 27% when compared to a placebo, according to a...











